Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;124(11):651-62.
doi: 10.1042/CS20120504.

Histone deacetylases as targets for treatment of multiple diseases

Jinhua Tang  1 , Haidong Yan, Shougang Zhuang
Affiliations
Review

Histone deacetylases as targets for treatment of multiple diseases

Jinhua Tang et al. Clin Sci (Lond). 2013 Jun.

Abstract

HDACs (histone deacetylases) are a group of enzymes that deacetylate histones as well as non-histone proteins. They are known as modulators of gene transcription and are associated with proliferation and differentiation of a variety of cell types and the pathogenesis of some diseases. Recently, HDACs have come to be considered crucial targets in various diseases, including cancer, interstitial fibrosis, autoimmune and inflammatory diseases, and metabolic disorders. Pharmacological inhibitors of HDACs have been used or tested to treat those diseases. In the present review, we will examine the application of HDAC inhibitors in a variety of diseases with the focus on their effects of anti-cancer, fibrosis, anti-inflammatory, immunomodulatory activity and regulating metabolic disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1. HDACI targets and downstream effects
Inhibition of HDACs by HDACIs induces acetylation of histone proteins, as well as non-histone proteins, which leads to the alteration in various physiological and pathological processes, including apoptosis/autophagy, cell cycle, fibrogenesis, immune response, inflammation and metabolism. Therefore HDACIs may be potent therapeutic agents for anticancer, antifibrosis, anti-inflammatory and immunomodulation, and regulating metabolic disorders.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012;90:85–94. - PubMed
    1. Inche AG, La Thangue NB. Chromatin control and cancer-drug discovery: realizing the promise. Drug Discovery Today. 2006;11:97–109. - PubMed
    1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discovery. 2006;5:769–784. - PubMed
    1. Nightingale KP, O’Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev. 2006;16:125–136. - PubMed
    1. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem. 2001;70:81–120. - PubMed

Publication types

MeSH terms